Daily Clinical Briefing · Educational reading for healthcare professionals
A functioning short peripheral IV can start vasopressors promptly, provided the site is closely monitored.
A needed vasopressor can start through an appropriate, functioning short peripheral IV rather than wait for central access.
Shock creates a sequencing problem when initial fluid resuscitation has not restored perfusion. A vasopressor is needed, but central venous access is not yet in place. The practical decision is whether obtaining that access should delay treatment.
The evidence reviewed in SGEM#522 supports a pressors-first, central-access-if-needed approach. An appropriate, well-functioning short peripheral IV can be used to start vasopressor treatment while blood pressure, peripheral perfusion and clinical response are reassessed.
That should not be translated into “peripheral vasopressors are safe”.
The review includes 49 studies: 31 retrospective studies, 14 prospective observational studies and four randomised controlled trials. Sixty-one per cent have an unclear or high risk of bias. The pooled incidence of minor adverse events is 2.3% per catheter, but the studies are highly heterogeneous and the outcome combines problems ranging from pain and swelling to extravasation, cellulitis and thrombophlebitis.
Major complications appear uncommon, but uncommon is not zero. Among 29,596 short peripheral IV catheters, one tissue-necrosis event required fasciotomy. That matters when a pooled major-event estimate rounds to 0.0%. It is reassuring evidence, but it cannot justify describing the treatment as risk-free.
Short peripheral IVs and midlines also need to be kept separate when interpreting the findings. All 30 reported venous thromboembolic events occurred in the midline studies.
Another attractive number is that 59.7% of catheters in the relevant analysis were associated with avoidance of central venous catheter placement. The heterogeneity around that estimate is substantial, and the principal analysis has no conventional central-line comparator. It therefore cannot show that peripheral administration caused central-line avoidance or that it is equally or more safe.
The bedside implication is simpler than the statistics. If a patient needs a vasopressor and has an appropriate functioning short peripheral IV, treatment need not wait solely for a central line. Check the site frequently for pain, swelling or extravasation. Titrate norepinephrine against blood pressure and peripheral perfusion, then keep reviewing the duration of treatment and whether central access has become necessary.
Healthy ageing is better framed around healthspan, function and prevention than simply lifespan. Social connection sits alongside diet, exercise and sleep, while the skin microbiome illustrates why adaptation and resilience matter more than eliminating every environmental exposure.
Adult coarctation decisions combine right-arm ambulatory blood pressure, catheter pressure gradient and anatomical narrowing. Suitable patients may undergo stenting, but successful repair does not end care: hypertension surveillance and lifelong imaging follow-up remain necessary.
A structured blood-gas approach starts with pH, carbon dioxide and bicarbonate before considering compensation. The anion gap then helps distinguish acid addition from bicarbonate loss, while vomiting, diarrhoea and hyperventilation demonstrate how mixed disturbances arise.
Career sustainability requires more than grit. Post-shift rumination, poor recovery and accumulated commitments can erode wellbeing, while deliberate detachment, self-compassion, manageable career changes, supportive relationships and staff involvement offer practical ways to make clinical work more sustainable.
Clinically indicated vasopressors can start through an appropriate, closely monitored short peripheral IV rather than waiting for central access. Serious complications appear uncommon, but heterogeneous, predominantly observational evidence does not establish equal or superior safety to central administration.
When shock persists despite initial fluid resuscitation, do not delay a clinically indicated vasopressor solely to obtain central access if an appropriate, functioning short peripheral IV is available. Check the site frequently for pain, swelling or extravasation and titrate norepinephrine against blood pressure and peripheral perfusion. Review ongoing vasopressor need and whether central access becomes necessary.
A patient remains hypotensive with poor peripheral perfusion despite initial fluid resuscitation. Norepinephrine is clinically indicated, a functioning short peripheral IV is available, and central venous access has not yet been obtained. Should vasopressor treatment wait for the central line?
No. A clinically indicated vasopressor can start through an appropriate, functioning short peripheral IV rather than being delayed solely for central access. The infusion site and clinical response require frequent reassessment.
A meta-analysis reports a pooled major-adverse-event estimate of 0.0% for peripheral vasopressors, but the included short peripheral IV studies contain one tissue-necrosis event requiring fasciotomy. How should the pooled estimate be interpreted?
It does not mean that serious complications cannot occur. The observed tissue injury demonstrates residual risk, while predominantly observational evidence and incomplete retrospective reporting further limit certainty.
An adult with aortic coarctation has hypertension and a catheter peak-to-peak gradient of 25 mmHg. Does the described pathway require greater than 50% aortic narrowing before intervention is considered?
No. Hypertension with a catheter peak-to-peak gradient above 20 mmHg supports referral for intervention. The greater than 50% anatomical narrowing threshold becomes relevant when the catheter gradient is below 20 mmHg.
Daily Clinical Briefings are prepared using ChatGPT Pro from the show notes and educational output for that day’s episodes. Iain Beardsell then checks the briefing for accuracy.
This describes the current briefing process. Item-specific review dates are shown only where documented. The original podcasts remain the sources; MedPod’s briefing is additional educational material.
Read about MedPod’s editorial approach
Report an error or source concern — please include the article title and link, without patient-identifying information.
.svg)